WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside of China

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi Biologics served at the site in Dundalk, executing a 20-year contract to produce vaccines worth $150 million annually.

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.

WuXi Biologics plans to sell its vaccine facility in Dundalk, Ireland to Merck & Co. for approximately $500 million. This comes as U.S. legislation aims to restrict WuXi Biologics business in the U.S. WuXi Biologics provided services for Merck at the site in Dundalk under a long-term contract to produce vaccines.

China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 million. The WuXi Biologics facility is located in Dundalk, Co Louth, in the IDA Science and Technology Park.

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.